Ropes & Gray Advises Everest Medicines on Agreement with Gilead Sciences for Cancer Drug Trodelvy in Asia Territories
Everest Medicines, advised by Ropes & Gray, announced on Aug. 16, 2022, that it has entered into an agreement with Immunomedics, Inc. under which Immunomedics will obtain exclusive rights to develop and commercialize cancer drug Trodelvy in Asia territories.
Source: ropesgray.com